Mutations in the analogous residue of ABL1 (L273M) and ErbB2 (L755S or P) (Figure 5C) have been described in patients with imatinib-resistant chronic myelogenous leukemia (CML) and solid tumors including gastric, breast, and lung cancers, respectively [35–37]. The gene discussed is ERBB2; the disease is lung carcinoma.